Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

VLP Therapeutics

Request full access

Developing innovative medical treatments to transform traditional vaccine and targeted antibody therapies

Rockville, United StatesFounded 2012Biotech & Life Sciences

About VLP Therapeutics

VLP Therapeutics is a biotechnology company developing next-generation therapeutic and prophylactic vaccines targeting cancer and infectious diseases, including malaria, dengue, and COVID-19. The company was founded in 2012 in Gaithersburg, Maryland, by Dr. Wataru Akahata, Dr. Ryuji Ueno, and Dr. Sachiko Kuno to translate innovative virus-like particle (VLP) vaccine technologies into clinical therapies.

The company originated from the work of Dr. Wataru Akahata, a virologist who conducted vaccine research at Kyoto University and later spent a decade at the U.S. National Institutes of Health (NIH) Vaccine Research Center. During his time at NIH, Akahata developed a virus-like particle vaccine for the Chikungunya virus, which received the NIH Director’s Award in 2012 and demonstrated the potential of VLP-based immunization approaches. Encouraged by co-founders Ueno and Kuno, Akahata established VLP Therapeutics to advance these technologies toward commercial vaccines.

VLP Therapeutics develops vaccines using two proprietary technology platforms: the inserted alphavirus virus-like particle (i-αVLP) platform and a self-amplifying RNA (replicon) platform. The i-αVLP platform uses virus-like particles that mimic the structure of viruses to trigger strong immune responses without containing genetic material, making them incapable of replication or infection, and is being applied to vaccines for cancer, malaria, and dengue. The replicon platform enables vaccine RNA to self-amplify within cells, allowing effective immune responses with smaller doses than conventional mRNA vaccines and supporting scalable manufacturing. The company’s pipeline includes a malaria vaccine candidate (VLPM-01) that has completed Phase 1 clinical trials, as well as vaccine programs for dengue, cancer immunotherapy, and COVID-19 in various stages of development.

To support its research and development activities, VLP Therapeutics has raised venture funding including a $16 million Series A round (March 2021) and a $21 million Series A-1 round (December 2021). Investors include Sojitz Corporation, MIYAKO Capital, Nobelpharma, and MUFG Bank.

The company operates internationally, with a subsidiary in Japan responsible for advancing RNA vaccine development and manufacturing capabilities.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
72.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, Woman Founder, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANT✓Other financing Nov 2025 $105K — Vinnova ↗
GRANT✓Other financing Nov 2025 $2.8M — Bill & Melinda Gates Foundation ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

VLP Therapeutics website traffic

Latest recorded traffic for VLP Therapeutics is 1.9K monthly website visits, up 18.8% over the last three months. VLP Therapeutics's team declined 14.3% over the past year.

Latest monthly visits1.9K 3-month web change+18.8% 1-year team growth-14.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

VLP Therapeutics in the Rockville ecosystem

Live from Dealroom

The VLP Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Global Health Innovative Technology Fund
  • Vinnova
  • Bill & Melinda Gates Foundation

Series A8 investors entered at this stage

  • Miyako Capital
  • Sojitz
  • RJ Fund
  • Robert Hisaoka
  • Konishiyasu Co
  • SK Impact Fund
  • MUFG Bank
  • Nobelpharma

Other known investors4 additional known investors

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about VLP Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See VLP Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.